Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …

Simple Summary The Ras-Raf-MEK-ERK signaling pathway is responsible for regulating
cell proliferation, differentiation and survival. Overexpression and overactivation of members …

Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively
increasing incidence rate has been observed in recent years, with 95% of thyroid cancer …

B-Raf kinase inhibitors such as vemurafenib (PLX4032) and dabrafenib have limited
therapeutic efficacy on BRAF-mutated thyroid cancer. Cancer stem cells (CSCs) play …

Synthetic lethality offers a promising approach for developing effective therapeutic
interventions in cancer when direct targeting of driver genes is impractical. In this study, we …

Mutations in BRAF are common in advanced papillary and anaplastic thyroid cancer (PTC
and ATC). However, patients with BRAF-mutant PTC currently lack therapies targeting this …

Triple‐negative breast cancer (TNBC) is the most malignant subtype of breast cancer. Some
microRNAs (miRNAs) were abnormally expressed in TNBC, and they are closely related to …

Cellular retinoic acid binding protein 1 (CRABP1) participates in the regulation of retinoid
signaling. Previous studies showed conflicting results regarding the role of CRABP1 in …

In vertical inhibition treatment strategies, multiple components of an intracellular pathway
are simultaneously inhibited. Vertical inhibition of the BRAFV600E–MEK-ERK signalling …

BRAF or RAS mutation-induced aberrant activation of the mitogen-activated protein kinase
(MAPK) pathway is frequently observed in human cancers. As the key downstream node of …